August 9, 2002

SynChem, Inc. wins Lilly’s 2002 Supplier Award

SynChem, Inc. was selected as one of Eli Lilly and Company's 2002 Supplier Award winners!(see detail from Lilly's website) There are 18 award winners for this year's suppliers throughout Lilly, including four in its research division. SynChem's representatives attended the awards presentation on August 8, 2002.

July 22, 2002

SynChem, Inc. and Neurocrine Biosciences, Inc. signed a collaboration agreement for combinatorial chemistry

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and SynChem, Inc. today announced that they have signed an agreement for the design and synthesis of a combinatorial chemistry template around small molecules targeted at the super-family of receptors called G protein coupled receptors (GPCRs). Under the terms of the agreement, SynChem will combine its expertise in the synthesis of new combinatorial chemistry templates with Neurocrine’s computational methodology and high throughput synthesis to design and synthesize a library targeted at GPCRs. Both companies will contribute unique, proprietary chemical templates to the Collaboration. Neurocrine has several research programs based on GPCRs, which serve as targets for the identification of novel therapeutics. "We are delighted to initiate this combinatorial chemistry collaboration with Neurocrine. We look forward to achieving success on behalf of Neurocrine and expanding our list of partners for whom we can provide this very valuable service” said Dr. W. Paul Mar, President and CEO of SynChem, Inc. “This is an excellent way for us acquire the complex intermediates that we need to develop our GPCR screening library which has been designed specifically for GPCR’s activated by peptide ligands” said John Saunders, Ph.D. Vice President of Research Chemistry for Neurocrine Biosciences.

Neurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

SynChem, Inc. is a privately held contract research organization providing research services in all aspects of organic chemistry. SynChem complements the experience of its researchers with proprietary tools in organic chemistry and combinatorial chemistry building blocks.